GlobeNewswire·Oct 12, 2026, 8:01 AM ET

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

ARDX

Ardelyx announced real-world analysis results at the ACG 2026 Annual Scientific Meeting showing a significant drop in gastrointestinal healthcare resource utilization after adults with IBS-C started IBSRELA (tenapanor).
A retrospective study of 470 patients revealed a reduction in median GI visits from 4.5 in the year prior to initiation to 3.0 in the year following initiation.
Significant reductions in healthcare utilization were observed across subgroups, including patients who had previously tried at least one IBS-C medication.
Ardelyx presented data on the burden of IBS-C symptoms on quality of life & the design of an ongoing Phase 3 study evaluating tenapanor for chronic idiopathic constipation (CIC).
IBSRELA is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3) indicated for the treatment of Irritable Bowel Syndrome with Constipation in adults.
The drug works by reducing sodium absorption to retain luminal water, accelerate intestinal transit, & soften stool consistency.
A Boxed Warning highlights the risk of serious dehydration in pediatric patients, with the drug contraindicated in those under 6 years of age.
Common adverse reactions include diarrhea (16%), abdominal distension (3%), flatulence (3%), & dizziness (2%).
Ardelyx also sponsored a Product Theater session on October 12th to discuss managing adult patients with IBS-C.
The company currently markets IBSRELA & XPHOZAH in the U.S. & is developing tenapanor for CIC as well as RDX10531 for multiple therapeutic areas.